The ESAIC is delighted to support the NIHR Global Health Research Unit on Global Surgery in the SURG-Week study.
This is a large, international, observational study that aims to determine the optimal timing of surgery following SARS-CoV-2 infection and to assess key global surgical indicators. All hospitals worldwide can participate, including those that have not admitted SARS-CoV-2 infected patients. All ages, all surgical specialities, any operation, and any patient regardless of SARS-CoV-2 status may be included. CovidSurg Collaborative is a global collaborative exploring the impact of COVID-19 in surgical patients and services.
2 main studies: CovidSurg Cohort study and CovidSurg-Cancer study are already in the closing phases as well as a modelling study
All hospitals. All specialities. All patients. One week of data collection.
- To determine the optimal timing of surgery following SARS-CoV-2 infection.
- Assess key global surgical indicators, such as postoperative mortality.
- All hospitals can participate in this study, including hospitals that have not admitted SARS-CoV-2 infected patients.
- All patients (from all specialities) undergoing a surgical procedure done in an operating theatre will be included (any SARS-CoV-2 status).
- All collaborators will be included as PubMed-citable co-authors on resulting publications.
Primary aim: To determine the optimal timing for surgery following SARS-CoV-2 infection
Secondary aim: Determine key global surgical indicators such as postoperative mortality rates
14th July – Study Lunch: Register your interest and seek study approvals
1st September – Team registration and REDCap access: Register your team for a REDCap account
October – Start of data collection: Your 7-day data collection period should start in October
+7 days 30 days follow-up
Collaborative Authorship: All collaborators recognised as PubMed citable co-authors in any publications resulting from these studies under ‘CovidSurg Collaborative.’